Lasa Supergenerics Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Lasa Supergenerics Ltd is ₹ 7.87 as of 05 May 15:30 . The P/E Ratio of Lasa Supergenerics Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Lasa Supergenerics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Lasa Supergenerics Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Lasa Supergenerics Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Lasa Supergenerics Ltd or Shilpa Medicare Ltd?

Market cap of Lasa Supergenerics Ltd is 39 Cr while Market cap of Shilpa Medicare Ltd is 8,300 Cr

What are the key factors driving the stock performance of Lasa Supergenerics Ltd and Shilpa Medicare Ltd?

The stock performance of Lasa Supergenerics Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lasa Supergenerics Ltd and Shilpa Medicare Ltd?

As of May 5, 2026, the Lasa Supergenerics Ltd stock price is INR ₹7.87. On the other hand, Shilpa Medicare Ltd stock price is INR ₹424.4.

How do dividend payouts of Lasa Supergenerics Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Lasa Supergenerics Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.